TLR9 and neoplasm: In MM, it was shown that a TLR9 agonist could restore the ability of patient-derived plasmacytoid dendritic cells (pDCs) to stimulate T-cell proliferation and that activating TLR9 in a xenograft MM model reduced tumor load (55).